404577-34-0

Basic information

• Product Name: (R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE
• Synonyms: (R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE;(R)-1-N-Boc-3-methanesulfonyloxypiperidine;(R)-3-methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester;(R)-1-Boc-3-mesyloxyl-piperidine
• CAS NO: 404577-34-0
• Molecular Formula: C₁₁H₂₁NO₅S
• Molecular Weight: 279.3531
• Mol File: 404577-34-0.mol

Chemical Properties

• Boiling Point: 407.2 °C at 760 mmHg
• Flash Point: 200.1 °C
• Appearance: /
• Density: 1.22 g/cm³
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE(404577-34-0)
• EPA Substance Registry System: (R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE(404577-34-0)

Safety Data

• Hazardous Substances Data: 404577-34-0(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
(R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE is used as a protecting group for the amino group of molecules in organic synthesis. It temporarily masks the amino group, preventing unwanted reactions until the protecting group is removed under specific conditions. This allows chemists to control the reactivity of the molecule and achieve selective reactions.
Used in Peptide Chemistry:
In peptide chemistry, (R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE serves as a protecting group for the amino group of amino acids during the synthesis of peptides. It ensures that the amino group remains unreacted until the desired peptide sequence is formed, and the protecting group is removed to reveal the free amino group for further reactions.
Used in Pharmaceutical Industry:
(R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE is used as a building block in the preparation of pharmaceuticals. Its unique structure and reactivity make it a valuable component in the synthesis of various drug molecules, contributing to the development of new therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical industry, (R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE is utilized as a building block for the synthesis of agrochemicals. Its incorporation into the molecular structures of these compounds can enhance their effectiveness in pest control and crop protection.
Overall, (R)-1-(TERT-BUTOXYCARBONYL)PIPERIDIN-3-YL METHANESULFONATE is a versatile chemical compound with significant applications in various fields, including organic synthesis, peptide chemistry, pharmaceuticals, and agrochemicals. Its ability to act as a protecting group and a building block makes it an essential component in the development of new and improved molecules for various applications.

Upstream product

• 91599-81-4 (R)-N-benzyl-3-hydroxypiperidine 
• 91599-79-0 (S)-1-N-benzyl-3-hydroxypiperidine 
• 940890-90-4 (S)-3-methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester 
• 14813-01-5 1-benzyl-3-hydroxypiperidine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 143900-44-1 tert-butyl (3S)-3-hydroxypiperidine-1-carboxylate 
• 143900-43-0 tert-butyl (3R)-3-hydroxypiperidine-1-carboxylate 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 143900-44-1 tert-butyl (3S)-3-hydroxypiperidine-1-carboxylate 
• 85275-46-3 tert-butyl (3R)-3-(p-tolylsulfonyloxy)piperidine-1-carboxylate 
• 940890-90-4 (S)-3-methanesulfonyloxy-piperidine-1-carboxylic acid tert-butyl ester 
• 143900-43-0 tert-butyl (3R)-3-hydroxypiperidine-1-carboxylate 
• 912761-71-8 (S)-3-m-tolyloxy-piperidine 
• 902836-20-8 C₁₇H₂₅NO₃ 
• 85838-94-4 N-Boc-1,2,3,6-tetrahydropyridine 
• 946725-84-4 (R)-3-(3-fluoro-phenoxy)-piperidine 
• 946725-84-4 (S)-3-(3-fluoro-phenoxy)-piperidine 

Relevant articles and documents

CXCR2 ANTAGONIST

A compound as a CXCR2 antagonist and an application thereof in preparing a drug as a CXCR2 antagonist. In particular, the present invention relates to a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof.

BROAD-SPECTRUM CARBAPENEMS

The present disclosure provides broad-spectrum carbapenem derivatives and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such derivatives and/or compositions.

Chiral-1-tert-butoxy-carbonyl-3-hydroxy-piperidine, and the preparation of chiral turning method

The invention relates to preparation of chirality-1-t-butyloxycarboryl-3-hydroxy piperidine and a method for chirality turning. The preparation mainly comprises the following steps: resolving N-benzyl-3-hydroxy piperidine as a raw material to obtain a (S) or (R)-1-benzyl-3-hydroxy piperidine camphorsulfonic acid salt, performing alkali freedom to obtain (S) or (R)-1-benzyl-3-hydroxy piperidine, performing palladium carbon hydrogenation debenzylation/t-butyloxycarboryl protection to obtain (S) or (R)-1-t-butyloxycarboryl-3-hydroxy piperidine, acylating substituting sulfonyl chloride of (R) or (S)-1-substituting-3-hydroxy piperidine as a raw material to obtain (R) or (S)-1-substituting-3-hydroxy piperidine sulfonate, substituting by using substituting carboxylate to obtain (S) or (R)-1-substituting-3-hydroxy piperidine carboxylic ester, and performing alkaline hydrolysis to obtain (S) or (R)-1-substituting-3-hydroxy piperidine. The synthesis route is gentle in reaction condition, and is applicable to industrial large-scale production.

Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor

A potent inhibitor of the JmjC histone lysine demethylase KDM2A (compound 35, pIC50 7.2) with excellent selectivity over representatives from other KDM subfamilies has been developed; the discovery that a triazolopyridine compound binds to the active site of JmjC KDMs was followed by optimisation of the triazole substituent for KDM2A inhibition and selectivity. This journal is

NEW INDANYLOXYDIHYDROBENZOFURANYLACETIC ACIDS

The present invention relates to compounds of general formula I, wherein the groups R1, R2 and m are defined as in claim 1, which have valuable pharmacological properties, in particular bind to the GPR40 receptor and modulate its activity. The compounds are suitable for treatment and prevention of diseases which can be influenced by this receptor, such as metabolic diseases, in particular diabetes type 2.

GAMMA SECRETASE INHIBITORS

Disclosed herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, wherein each of the substituents is given the definition as set forth in the specification and claims. Also disclosed are pharmaceutical compositions containing t

Constrained (l-)-S-adenosyl-l-homocysteine (SAH) analogues as DNA methyltransferase inhibitors

Potent SAH analogues with constrained homocysteine units have been designed and synthesized as inhibitors of human DNMT enzymes. The five membered (2S,4S)-4-mercaptopyrrolidine-2-carboxylic acid, in 1a, was a good replacement for homocysteine, while the corresponding six-member counterpart was less active. Further optimization of 1a, changed the selectivity profile of these inhibitors. A Chloro substituent at the 2-position of 1a, compound 1d, retained potency against DNMT1, while N6 alkylation, compound 7a, conserved DNMT3b2 activity. The concomitant substitutions of 1a at both 2- and N6 positions reduced activity against both enzymes.

Identification of novel series of human CCR1 antagonists

A hit-to-lead optimization process was carried out on the high throughput screening hit compound 1 resulting in the identification of several potent and selective CCR1 receptor antagonists. Compound 37 shows the best overall profile with IC50 values of 100 nM in binding and functional assays.

Isoquinoline derivatives

The invention relates to isoquinoline derivatives having the general Formula I wherein X is O, S or NH; Y is OH or NH2; m is 0, 1 or 2; n is 1 or 2; R1 is H, when Y is NH2; or R. is H, (C1-4)alkyl or halogen, when Y is OH; R2 and R3 are independently H, (C1-4)alkyl or halogen; R is H or (C1-6)alkyl, optionally substituted with OH, (C1-4)-alkyloxy, (C1-4)alkyloxycarbonyl, (C3-7)cycloalkyl, which may optionally comprise a heteroatom selected from O and S, (C6-10)aryl, (C6-10)aryloxy or a 5- or 6-membered heteroaryl group comprising 1-3 heteroatoms independently selected from O, N and S, each aryl or heteroaryl group being optionally substituted with 1-3 substituents independently selected from (C1-4)alkyl, (C1-4)alkyloxy, (C1-4)alkylsulfonyl and halogen; or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising the same as well as to the use of the isoquinoline derivatives in the treatment of ROCK-I related disorders such as hypertension, atherosclerosis and glaucoma.